home technology applications about us news
Amino Acid Analysis using HPCE - a poster from Analytix 2012 exhibition in Beijing.  deltaDOT’s core technology showing Label Free Intrinsic Imaging (LFII®) applied to indirect  UV measurements, using a UV-absorbing buffer. This allows the transmission of light as the  non-UV-absorbing analytes pass the detector window. Indirect UV can be used in the analysis  of substances inaccessible to the normal CE methodology. (...more)
Amino Acid Analysis poster, Beijing 2012
LFII® in HPCE How it works poster, Beijing 2012 
Label Free Intrinsic Imaging (LFII®) is a methodology of analysis which removes a whole class  of systematic errors associated with labels and stains, using the absorbance characteristics of  the molecule as defined by Beers Law. In proteomics, typically the peptide bond between each  amino acid is detected at 214nm. LFII® has also been applied in the analysis of Peptides and  Amino Acids, of small molecules and in Baculovirus Expression system titres (...more)
We were set up as an Imperial spin-out in November 2000 and rented space in several of the  college’s departments during our first five years. For the past five years we have been based in  the Imperial Incubator on the College’s South Kensington campus. Being based in an  incubator, instead of an academic department, has helped us make the transition into being a  commercial company. Although we are now at LBIC, strong links remain between deltaDOT  and research groups at Imperial that are using our technology (...more) 
LBIC News article Summer 2011 
Biopharmaceutical HPCE Applications poster, Beijing 2012 
deltaDOT’s Label Free Intrinsic Imaging (LFII®) systems enable higher quality separations  than existing CE technologies – allowing direct monitoring of unlabelled biomolecules,  reducing the cost and time per analysis. Advantages of LFII® in Capillary Electrophoresis over  traditional techniques include: Accuracy and Precision / Efficient separation / High resolution /  Rapid analysis / direct oncapillary Quantitation / Economy (...more)
Clinical collaboration with Royal Veterinary College
A Label-Free High Performance Capillary Electrophoresis (HPCE). method developed by  deltaDOT for the determination of Glomerular Filtration Rate (GFR) values in feline subjects  administered with contrast agent Iohexol. This CE technique was found to give quick result  with minimum sample preparation and lower costs as compared with traditional HPLC  (...more) 
18 January 2018 deltaDOT Ltd. announce successful licensing of their High Performance  Capillary Electrophoresis technology (HPCE) to a leading Chinese company. Last month  deltaDOT entered into a collaboration agreement with a Chinese partner to purchase all  deltaDOT’s technical know-how, software and IP licenses for their High Performance Capillary  Electrophoresis (HPCE) technology (...more)  18 December 2017 The subject of the new Technology partnership publication by deltaDOT is  Glatiramer Acetate Analysis as applied in immunomodulator treatment for multiple sclerosis. On demand analytics of high quality and cost effective nature are described in this application note  (...more)  13 October 2017 deltaDOT continues with Technology partnership publication (www.ttp.com)  The TTP Journal of Technology and Business Innovation provides technical insight into UK  advanced scientific businesses. New articles are now available on Water Ionic Analysis (...more)  and Nicotine Analysis (...more).  8 September 2017 deltaDOT are launching a new series of articles dD Techniques on the  capabilities of their High Performance Label Free Imaging Capillary Electrophoresis technology.  The articles offer accessible information and an insight into this unique technology which is used  worldwide to solve challenging analytical problems. A new perspective on the tools required for  the development and manufacture of monoclonal antibodies, biosimilars, stratified therapies,  viral vaccines and gene therapy vectors highlights the need for new analytical techniques.  These new perspectives are the aims which dD Techniques articles intend to deliver to a wide  range of audience (...links to article1, article2, article3)  24 August 2017 The Technology partnership publication (www.ttp.com) now includes key facts  and data on deltaDOT’s High Precision Capillary Electrophoresis advanced technology. The TTP  Journal of Technology and Business Innovation provides technical insight into UK advanced  scientific businesses (...more) 3rd July 2017 Future Targeted Healthcare Manufacturing. deltaDOT announce their  participation in the new EPSRC funded Future Targeted Healthcare Manufacturing Hub, led by  UCL (...more). The Hub will address the manufacturing, business and regulatory challenges to  ensure that new targeted biological medicines can be developed quickly and manufactured at  affordable costs (...more).   24th January 2017 – deltaDOT Ltd. announces compliance with CFR 21 part 11 of USA’s Food  and Drug Administration. deltaDOT now offers an upgraded version of its control and analysis  software which has been designed to aid users of deltaDOT’s HPCE-512 Hig Performance  Capillary Electrophoresis instrument in achieving compliance with CFR 21 part 11.The upgrade  package contains controls to help meet the stringent requirements of CFR 21 part 11 including  the system access by authorised personel only, maintaining audit trails of user actions,  generating complete and protected data files and the application of electronic signatures to data  (...more)  20 Sep 2016 National Health Service Quality Control North West (QCNW) Liverpool  labs  presented the data on monoclonal antibody stability trials based on deltaDOT’s Capillary  Electrophoresis (CE) technology  and expertise. They state that CE technology is suitable for  monitoring the stability of monoclonal antibodies and can perform purity and charge analysis with  high resolution and repeatability. They conclude that CE can replace other techniques commonly  used for this analysis IEC and SDS PAGE (link to the poster).  3rd July 2016 Monoclonal Antibody Stability Trials using deltaDOT HPCE-512 technology  reported by Dr. Deepika Devanur. Now available in pdf slide format on our website (...more) 
Quality Control of Glycoproteins
Biopharmaceuticals are of ever increasing importance in the pharma industry, with the current  market share of over 20% expected to rise steadily year after year 1. The efficacy and safety  of protein based pharmaceuticals are influenced not only by primary, secondary and tertiary  structure, but also by various post translational modifications (PTM), with glycosylation being  the most common (...more)